PROTONIX for ORAL SUSP

Compare PROTONIX for ORAL SUSP  to:
Compare
Compare

Generic Name for PROTONIX for ORAL SUSP

Pantoprazole (as sodium) 40mg; per packet; e-c delayed-release granules.

Legal Classification:

Rx

Pharmacological Class for PROTONIX for ORAL SUSP

Proton pump inhibitor.

Manufacturer of PROTONIX for ORAL SUSP

Pfizer Labs

Indications for PROTONIX for ORAL SUSP

Short-term treatment and maintenance of healing of erosive esophagitis (EE). Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult dose for PROTONIX for ORAL SUSP

Swallow whole. Do not crush or chew granules. Susp: Take 30mins before a meal. Mix contents of packet in 5mL of apple juice or applesauce (do not mix in water, other liquids or foods); then swallow. May give via NG tube (see literature). Treatment of EE: 40mg once daily for ≤8 weeks; if not healed, may repeat for 8 more weeks. Maintenance of EE healing: 40mg once daily. Pathological hypersecretory conditions: initially 40mg twice daily; max 240mg/day.

Children's dosing for PROTONIX for ORAL SUSP

Swallow whole. Do not crush or chew granules. Susp: Take 30mins before a meal. Mix contents of packet in 5mL of apple juice or applesauce (do not mix in water, other liquids or foods); then swallow. May give via NG tube (see literature). <5yrs: not recommended. Treatment of EE: Give once daily for up to 8 weeks. ≥5yrs: (≥15kg to <40kg): 20mg; (≥40kg): 40mg.

Also:

Warnings/Precautions for PROTONIX for ORAL SUSP

Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for PROTONIX for ORAL SUSP

Concomitant atazanavir or nelfinavir: not recommended. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron, ampicillin). Monitor warfarin. May give antacids concomitantly. IV form chelates metal ions. May cause false (+) urine THC test.

Adverse Reactions for PROTONIX for ORAL SUSP

Headache, GI upset, dizziness, arthralgia, inj site reactions; also children: upper respiratory infection, fever, rash, abdominal pain; rare: cyanocobalamin deficiency.

How is PROTONIX for ORAL SUSP supplied?

Tabs—90
Susp—30 packets/box
Vials (40mg)—1

Related Disease:

GERD {GERD}
Hypersecretory conditions~Zollinger-Ellison syndrome

Related Resources

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions